[Successful Hemostasis with Chemoradiotherapy for Unresectable Large HER2-Positive Advanced Gastric Cancer with Massive Bleeding-A Case Report].
In this case report, we explored the effectiveness of chemoradiotherapy(CRT)for an unresectable large HER2-positive advanced gastric cancer in a 67-year-old male patient.
APA
Miyake H, Fujii Y, et al. (2025). [Successful Hemostasis with Chemoradiotherapy for Unresectable Large HER2-Positive Advanced Gastric Cancer with Massive Bleeding-A Case Report].. Gan to kagaku ryoho. Cancer & chemotherapy, 52(6), 463-466.
MLA
Miyake H, et al.. "[Successful Hemostasis with Chemoradiotherapy for Unresectable Large HER2-Positive Advanced Gastric Cancer with Massive Bleeding-A Case Report].." Gan to kagaku ryoho. Cancer & chemotherapy, vol. 52, no. 6, 2025, pp. 463-466.
PMID
40563153
Abstract
In this case report, we explored the effectiveness of chemoradiotherapy(CRT)for an unresectable large HER2-positive advanced gastric cancer in a 67-year-old male patient. The patient presented with upper abdominal distension and severe anemia. Contrast-enhanced CT scan revealed a 13 cm large tumor in the stomach, with multiple metastases to the liver and lungs. The patient was treated with CRT, combining radiotherapy with FOLFOX chemotherapy to manage persistent massive bleeding. Bleeding was successfully controlled within approximately 2 weeks, eliminating the need for further transfusions and allowing the patient to resume oral intake. Following CRT, trastuzumab-based chemotherapy resulted in significant tumor shrinkage, enabling continued treatment. This case highlights the potential of CRT as an effective treatment option for unresectable HER2-positive advanced gastric cancer complicated by massive bleeding. The successful control of bleeding using CRT might improve both the prognosis and quality of life(QOL)for such patients. We present this case to highlight the therapeutic benefits of CRT in similar clinical scenarios.
MeSH Terms
Humans; Stomach Neoplasms; Male; Aged; Chemoradiotherapy; Erb-b2 Receptor Tyrosine Kinases; Hemorrhage; Antineoplastic Combined Chemotherapy Protocols